Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6494)
All Articles published online
|
Publishing Process of This Article
|
Jul 18, 2016 (publication date) through Jun 9, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Hasin Y, Shteingart S, Dahari H, Gafanovich I, Floru S, Braun M, Shlomai A, Verstandig A, Dery I, Uprichard SL, Cotler SJ, Lurie Y. Hepatitis C virus cures after direct acting antiviral-related drug-induced liver injury: Case report. World J Hepatol 2016; 8(20): 858-862 [PMID: 27458506 DOI: 10.4254/wjh.v8.i20.858] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v8/i20/858.htm |
| Number | Citing Articles |
| 1 |
Mayadah M. Abdelsalam, Nageh El-Mahdy, Sabry Abou-Saif. Direct-acting antivirals sofosbuvir and daclatasvir attenuate carbon tetrachloride-induced liver fibrosis in mice. Liver Research 2023; 7(1): 71 doi: 10.1016/j.livres.2023.02.001
|
| 2 |
Ohad Etzion, Harel Dahari, David Yardeni, Assaf Issachar, Anat Nevo-Shor, Michal Cohen-Naftaly, Yaffa Ashur, Susan L. Uprichard, Orly Sneh Arbib, Daniela Munteanu, Marius Braun, Scott J. Cotler, Naim Abufreha, Ayelet Keren-Naus, Yonat Shemer-Avni, Orna Mor, Jayanah Murad, Victor Novack, Amir Shlomai. Response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients: a Pilot study. Scientific Reports 2020; 10(1) doi: 10.1038/s41598-020-74568-x
|
| 3 |
Ashish Goyal, Yoav Lurie, Eric G. Meissner, Marian Major, Natasha Sansone, Susan L. Uprichard, Scott J. Cotler, Harel Dahari. Modeling HCV cure after an ultra-short duration of therapy with direct acting agents. Antiviral Research 2017; 144: 281 doi: 10.1016/j.antiviral.2017.06.019
|
| 4 |
Crina Fofiu, Alina Boeriu, Felicia Coman, Alexandru Fofiu, Nikola Panic, Milutin Bulajic, Daniela Dobru. Interferon-Free Regimen: Equally Effective in Treatment Naive and Experienced HCV Patients. Annals of Hepatology 2019; 18(1): 137 doi: 10.5604/01.3001.0012.7905
|
| 5 |
Rosa Zampino, Martina Vitrone, Antonio Parrella, Enrico Ragone, Emanuele Durante-Mangoni. Can we go for a shorter treatment course in chronic hepatitis C? More inspiring cases. Journal of Chemotherapy 2018; 30(2): 129 doi: 10.1080/1120009X.2017.1376782
|
| 6 |
Subhasish Baral, Rahul Roy, Narendra M Dixit. Modeling how reversal of immune exhaustion elicits cure of chronic hepatitis C after the end of treatment with direct‐acting antiviral agents. Immunology & Cell Biology 2018; 96(9): 969 doi: 10.1111/imcb.12161
|
| 7 |
Vinicius Lins Ferreira, Leticia Paula Leonart, Ana Maria Della Rocca, Roberto Pontarolo. Analysis of Safety Outcomes in Chronic Hepatitis C Patients using Interferon-free Treatment: A Systematic Review of Case Reports. Current Drug Therapy 2019; 14(3): 210 doi: 10.2174/1574885514666190130162547
|
| 8 |
Omar Shahbaz, Sandeep Mahajan, James H. Lewis. Highlights of drug - and herb- induced liver injury in the literature from 2016: how best to translate new information into clinical practice?. Expert Opinion on Drug Metabolism & Toxicology 2017; 13(9): 935 doi: 10.1080/17425255.2017.1362391
|
| 9 |
Rubesh Raja, Subhasish Baral, Narendra M. Dixit. Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon‐free treatment era. Immunological Reviews 2018; 285(1): 55 doi: 10.1111/imr.12689
|